Please login to the form below

Not currently logged in
Email:
Password:

Akinion’s Dr Richard Jones joins Holostem Terapie Avanzate

He takes on the role of chief executive officer

Holostem Terapie Avanzate Dr Richard JonesModena, Italy-based Holostem Terapie Avanzate has appointed Dr Richard Jones as its chief executive officer.

Dr Jones moves to the cell and gene therapy specialist from Swedish biotech Akinion Pharmaceuticals, where he had served as chief executive since January last year.

He brings over two decades of industry experience to the position, including from Novartis, where he was vice president and medicines commercialisation leader for haematology and global oncology.

Prior to this, Dr Jones served as vice president, global haematology medicines leader at GlaxoSmithKline, and has also held posts at Genzyme and Shire.

Dr Paolo Chiesi, chairman of the board at Holostem, said: “On behalf of the Holostem board, I am delighted to welcome Richard to the company.

“He brings a unique combination of international and rare disease expertise, crucial for this stage of Holostem's evolution.

“We look forward to working with Richard on the continued growth of the company's development and the realisation of the potential of the technology platform.”

2nd February 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....